Table 5 The cost-effectiveness ratios of high risk-based breast cancer screening strategies in Urban Hebei Province.
From: Cost-effectiveness evaluation of risk-based breast cancer screening in Urban Hebei Province
Strategy | ACER | ICER | ||||||
|---|---|---|---|---|---|---|---|---|
Cost | Benefit | Δ Cost* | Δ Benefit* | ACER | Δ Cost | Δ Benefit (QALY) | ICER (per QALY) | |
No screening | 26,611.76 | 17.71 | – | – | – | NA | NA | NA |
US screening triennially | 31,138.89 | 17.73 | 4527.13 | 0.03 | 170,038.67 | ED | ED | ED |
US screening biennially | 31,174.57 | 17.74 | 4562.81 | 0.03 | 148,463.27 | ED | ED | ED |
US screening annually | 31,366.35 | 17.75 | 4754.59 | 0.04 | 116,176.15 | 0.04 | 4754.59 | 116,176.15 |
MM screening triennially | 34,369.99 | 17.73 | 7758.23 | 0.03 | 265,554.88 | D | D | D |
MM screening biennially | 34,710.45 | 17.74 | 8098.69 | 0.03 | 232,435.04 | D | D | D |
MM screening annually | 35,833.23 | 17.75 | 9221.47 | 0.05 | 188,963.87 | 0.01 | 4466.88 | 567,261.63 |
US + MM screening triennially | 36,045.47 | 17.74 | 9433.71 | 0.03 | 312,164.66 | D | D | D |
US + MM screening biennially | 36,620.15 | 17.74 | 10,008.39 | 0.04 | 274,677.25 | D | D | D |
US + MM screening annually | 38,266.52 | 17.76 | 11,654.76 | 0.05 | 224,757.08 | 0 | 2433.29 | 796,560.57 |
